CCX507-B

CCX507-B is an orally administered small molecule inhibitor of the C-C chemokine receptor type 9 (CCR9), developed by ChemoCentryx as a second-generation treatment for inflammatory bowel diseases (IBD). CCR9 is a chemokine receptor primarily expressed on gut-homing T cells, and its interaction with the ligand CCL25 (TECK) is critical for the recruitment of these cells to the intestinal mucosa. By blocking CCR9, CCX507-B aims to reduce intestinal inflammation in conditions such as Crohn's disease and ulcerative colitis. The "-B" suffix likely refers to a specific salt or formulation used in clinical development. In Phase I studies, the compound demonstrated dose-proportional pharmacokinetics and high occupancy of CCR9 on circulating leukocytes.

Other names

CCX507-BCCX-507-BCCX 507-B